Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

itical appraisal of axitinib in the treatment of advanced renal cell carcinoma Review (475) Total Article Views Authors: Ansari J, Hussain SA, Ansari A, Glaholm J Published Date February 2013 Volume 2013:7 Pages 39 - 46 DOI: http://dx.doi.org/10.2147/BTT.S25862 Received: 21 August 2012 Accepted: 22 November 2012 Published: 28 February 2013 Jawaher Ansari,1 Syed A Hussain,2 Asif Ansari,3 John Glaholm4 1Beatson West of Scotland Cancer Centre, Glasgow, UK; 2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 3Cleveland Clinic, Cleveland, Ohio, USA; 4University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UK Abstract: A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.